William B Isaacs

List of Publications by Citations

340 papers	31,364 citations	89 h-index	168 g-index
359 ext. papers	35,490 ext. citations	8.6 avg, IF	6.43 L-index

#	Paper	IF	Citations
340	AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. *New England Journal of Medicine*, **2014**, 371, 1028-38	59.2	1753
339	Inflammation in prostate carcinogenesis. *Nature Reviews Cancer*, **2007**, 7, 256-69	31.3	1168
338	Prostate cancer. *New England Journal of Medicine*, **2003**, 349, 366-81	59.2	883
337	The evolutionary history of lethal metastatic prostate cancer. *Nature*, **2015**, 520, 353-357	50.4	857
336	Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. *Cancer Research*, **2009**, 69, 16-22	10.1	779
335	Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. *Nature Genetics*, **2007**, 39, 631-7	36.3	739
334	REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. *American Journal of Human Genetics*, **2016**, 99, 877-885	11	722
333	Evidence for a prostate cancer susceptibility locus on the X chromosome. *Nature Genetics*, **1998**, 20, 175-9	36.3	592
332	Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. *Nature Genetics*, **1995**, 11, 210-2	36.3	554
331	Cumulative association of five genetic variants with prostate cancer. *New England Journal of Medicine*, **2008**, 358, 910-9	59.2	526
330	Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. *Nature Medicine*, **2009**, 15, 559-65	50.5	513
329	Hereditary prostate cancer: epidemiologic and clinical features. *Journal of Urology*, **1993**, 150, 797-802	2.5	437
328	Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. *Nature Genetics*, **2010**, 42, 668-75	36.3	436
327	Germline mutations in HOXB13 and prostate-cancer risk. *New England Journal of Medicine*, **2012**, 366, 141-9	59.2	424
326	Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. *Cancer Research*, **2012**, 72, 3457-62	10.1	417
325	Hypermethylation of CpG islands in primary and metastatic human prostate cancer. *Cancer Research*, **2004**, 64, 1975-86	10.1	416
324	Pathological and molecular aspects of prostate cancer. *Lancet, The*, **2003**, 361, 955-64	40	361

323	Tracking the clonal origin of lethal prostate cancer. *Journal of Clinical Investigation*, **2013**, 123, 4918-22	15.9	355
322	Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. *Prostate*, **1986**, 9, 261-81	4.2	350
321	Cyclooxygenases in cancer: progress and perspective. *Cancer Letters*, **2004**, 215, 1-20	9.9	341
320	Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. *Cancer Research*, **2002**, 62, 2220-6	10.1	339
319	A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. *Nature Genetics*, **2014**, 46, 1103-9	36.3	331
318	Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. *Nature Genetics*, **2008**, 40, 281-3	36.3	327
317	Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. *Clinical Cancer Research*, **2008**, 14, 3254-61	12.9	314
316	Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. *Modern Pathology*, **2008**, 21, 1156-67	9.8	301
315	Prostate carcinogenesis and inflammation: emerging insights. *Carcinogenesis*, **2005**, 26, 1170-81	4.6	295
314	Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. *Nature Genetics*, **2002**, 32, 321-5	36.3	283
313	PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. *Clinical Cancer Research*, **2011**, 17, 6563-73	12.9	266
312	Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes. *Science*, **2014**, 345, 1251343	33.3	250
311	The landscape of recombination in African Americans. *Nature*, **2011**, 476, 170-5	50.4	243
310	Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. *Journal of the National Cancer Institute*, **2007**, 99, 1836-44	9.7	218
309	Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. *Clinical Cancer Research*, **2014**, 20, 890-903	12.9	215
308	Human prostate cancer precursors and pathobiology. *Urology*, **2003**, 62, 55-62	1.6	212
307	DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. *Cancer Research*, **2008**, 68, 8954-67	10.1	209
306	Identification of a new prostate cancer susceptibility locus on chromosome 8q24. *Nature Genetics*, **2009**, 41, 1055-7	36.3	201

305	Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the CAncer Prostate in Sweden Study. *Cancer Research*, **2004**, 64, 2918-22	10.1	199
304	DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. *Science Translational Medicine*, **2013**, 5, 169ra10	17.5	190
303	A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. *Cancer Research*, **2005**, 65, 1213-22	10.1	182
302	Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. *European Urology*, **2015**, 67, 470-9	10.2	181
301	GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. *American Journal of Pathology*, **2001**, 159, 1815-26	5.8	180
300	Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. *Prostate*, **2009**, 69, 1694-703	4.2	173
299	Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. *European Urology*, **2017**, 71, 740-747	10.2	171
298	Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. *Nature Genetics*, **2011**, 43, 570-3	36.3	171
297	A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. *Prostate*, **2011**, 71, 1656-67	4.2	159
296	Detection and analysis of beta-catenin mutations in prostate cancer. *Prostate*, **2000**, 45, 323-34	4.2	156
295	Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. *Genes Chromosomes and Cancer*, **1997**, 19, 90-96	5	146
294	In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis. *Oncogene*, **2002**, 21, 2679-94	9.2	145
293	Genome-wide association study identifies new prostate cancer susceptibility loci. *Human Molecular Genetics*, **2011**, 20, 3867-75	5.6	143
292	Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment. *Journal of Cellular Biochemistry*, **2004**, 91, 459-77	4.7	143
291	Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. *Nature Genetics*, **2008**, 40, 1153-5	36.3	139
290	Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. *Journal of the National Cancer Institute*, **2005**, 97, 525-32	9.7	139
289	Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of african descent. *Prostate Cancer*, **2013**, 2013, 560857	1.9	136
288	CYP3A4-V and prostate cancer in African Americans: causal or confounding association because of population stratification?. *Human Genetics*, **2002**, 110, 553-60	6.3	136

287	HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). *Human Genetics*, **2013**, 132, 5-14	6.3	134
286	Ligand-dependent inhibition of beta-catenin/TCF signaling by androgen receptor. *Oncogene*, **2002**, 21, 8453-69	9.2	133
285	A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms. *Prostate*, **2008**, 68, 306-20	4.2	131
284	DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies. *Prostate*, **2007**, 67, 692-700	4.2	129
283	A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. *American Journal of Human Genetics*, **2005**, 77, 219-29	11	129
282	Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer. *Prostate*, **2005**, 63, 316-23	4.2	129
281	Linkage and association studies of prostate cancer susceptibility: evidence for linkage at 8p22-23. *American Journal of Human Genetics*, **2001**, 69, 341-50	11	127
280	Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. *Journal of the National Cancer Institute*, **2007**, 99, 1525-33	9.7	120
279	Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2′,5′-oligoadenylates. *Cancer Research*, **2003**, 63, 6795-801	10.1	118
278	Macrophage inhibitory cytokine 1: a new prognostic marker in prostate cancer. *Clinical Cancer Research*, **2009**, 15, 6658-64	12.9	117
277	Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis. *Prostate*, **2008**, 68, 11-9	4.2	116
276	Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. *Nature Genetics*, **2018**, 50, 682-692	36.3	112
275	A novel role of myosin VI in human prostate cancer. *American Journal of Pathology*, **2006**, 169, 1843-54	5.8	112
274	Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis. *Prostate*, **2002**, 51, 189-200	4.2	110
273	Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas. *Prostate*, **1995**, 26, 35-9	4.2	110
272	A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. *Human Molecular Genetics*, **2013**, 22, 408-15	5.6	109
271	Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II. *Prostate*, **2009**, 69, 874-85	4.2	108
270	Structure and methylation-associated silencing of a gene within a homozygously deleted region of human chromosome band 8p22. *Genomics*, **1996**, 35, 55-65	4.3	108

269	Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. *European Urology*, **2018**, 74, 218-225	10.2	107
268	Acute inflammatory proteins constitute the organic matrix of prostatic corpora amylacea and calculi in men with prostate cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 3443-8	11.5	107
267	Human polymorphisms at long non-coding RNAs (lncRNAs) and association with prostate cancer risk. *Carcinogenesis*, **2011**, 32, 1655-9	4.6	107
266	Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. *Journal of Clinical Oncology*, **2018**, 36, 414-424	2.2	107
265	Associations between hOGG1 sequence variants and prostate cancer susceptibility. *Cancer Research* , **2002**, 62, 2253-7	10.1	105
264	Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2013**, 22, 2333-44	4	104
263	Explaining racial differences in prostate cancer in the United States: sociology or biology?. *Prostate*, **2005**, 62, 243-52	4.2	102
262	Physical mapping of chromosome 8p22 markers and their homozygous deletion in a metastatic prostate cancer. *Genomics*, **1996**, 35, 46-54	4.3	101
261	Sequence variants at 22q13 are associated with prostate cancer risk. *Cancer Research*, **2009**, 69, 10-5	10.1	100
260	H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer. *Journal of the National Cancer Institute*, **2004**, 96, 1248-54	9.7	99
259	Characterizing genetic risk at known prostate cancer susceptibility loci in African Americans. *PLoS Genetics*, **2011**, 7, e1001387	6	98
258	Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma. *Prostate*, **2003**, 57, 134-9	4.2	98
257	Polygenic risk score improves prostate cancer risk prediction: results from the Stockholm-1 cohort study. *European Urology*, **2011**, 60, 21-8	10.2	97
256	Alpha-methylacyl-CoA racemase: a variably sensitive immunohistochemical marker for the diagnosis of small prostate cancer foci on needle biopsy. *American Journal of Surgical Pathology*, **2003**, 27, 1128-33	6.7	97
255	Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer. *Cancer Research*, **2003**, 63, 7365-76	10.1	93
254	Fine mapping association study and functional analysis implicate a SNP in MSMB at 10q11 as a causal variant for prostate cancer risk. *Human Molecular Genetics*, **2009**, 18, 1368-75	5.6	91
253	Inherited genetic variant predisposes to aggressive but not indolent prostate cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 2136-40	11.5	90
252	Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer. *American Journal of Human Genetics*, **2001**, 68, 901-11	11	87

251	The role of genetic markers in the management of prostate cancer. *European Urology*, **2012**, 62, 577-87	10.2	86
250	Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. *Prostate*, **2009**, 69, 1195-205	4.2	86
249	Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer. *Neoplasia*, **2008**, 10, 897-907	6.4	86
248	COX-2 gene promoter haplotypes and prostate cancer risk. *Carcinogenesis*, **2004**, 25, 961-6	4.6	85
247	Modulation of CXCL14 (BRAK) expression in prostate cancer. *Prostate*, **2005**, 64, 67-74	4.2	85
246	Common sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. *American Journal of Human Genetics*, **2003**, 72, 208-12	11	81
245	Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. *Journal of Clinical Oncology*, **2020**, 38, 2798-2811	2.2	80
244	Validation of genome-wide prostate cancer associations in men of African descent. *Cancer Epidemiology Biomarkers and Prevention*, **2011**, 20, 23-32	4	79
243	Linkage of prostate cancer susceptibility loci to chromosome 1. *Human Genetics*, **2001**, 108, 335-45	6.3	79
242	MSH2 Loss in Primary Prostate Cancer. *Clinical Cancer Research*, **2017**, 23, 6863-6874	12.9	78
241	Focus on prostate cancer. *Cancer Cell*, **2002**, 2, 113-6	24.3	74
240	Genome-wide scan for prostate cancer susceptibility genes in the Johns Hopkins hereditary prostate cancer families. *Prostate*, **2003**, 57, 320-5	4.2	74
239	Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial. *European Urology*, **2012**, 62, 953-61	10.2	73
238	Assembly of inflammation-related genes for pathway-focused genetic analysis. *PLoS ONE*, **2007**, 2, e1035	3.7	73
237	Trefoil factor 3 overexpression in prostatic carcinoma: prognostic importance using tissue microarrays. *Prostate*, **2004**, 61, 215-27	4.2	73
236	Relation between aberrant alpha-catenin expression and loss of E-cadherin function in prostate cancer. *International Journal of Cancer*, **1997**, 74, 374-7	7.5	71
235	Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer. *European Urology*, **2019**, 75, 743-749	10.2	71
234	A polymorphism in the CDKN1B gene is associated with increased risk of hereditary prostate cancer. *Cancer Research*, **2004**, 64, 1997-9	10.1	70

233	In Swedish families with hereditary prostate cancer, linkage to the HPC1 locus on chromosome 1q24-25 is restricted to families with early-onset prostate cancer. *American Journal of Human Genetics*, **1999**, 65, 134-40	11	70
232	Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells. *Prostate*, **1994**, 25, 249-65	4.2	70
231	DIAPH3 governs the cellular transition to the amoeboid tumour phenotype. *EMBO Molecular Medicine*, **2012**, 4, 743-60	12	69
230	Estimation of absolute risk for prostate cancer using genetic markers and family history. *Prostate*, **2009**, 69, 1565-72	4.2	69
229	Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer. *Prostate*, **2018**, 78, 401-407	4.2	68
228	Genetic markers associated with early cancer-specific mortality following prostatectomy. *Cancer*, **2013**, 119, 2405-12	6.4	68
227	XMRV: a new virus in prostate cancer?. *Cancer Research*, **2010**, 70, 10028-33	10.1	68
226	Association of a germ-line copy number variation at 2p24.3 and risk for aggressive prostate cancer. *Cancer Research*, **2009**, 69, 2176-9	10.1	68
225	Acne and risk of prostate cancer. *International Journal of Cancer*, **2007**, 121, 2688-92	7.5	66
224	Phenotypic characterization of telomerase-immortalized primary non-malignant and malignant tumor-derived human prostate epithelial cell lines. *Experimental Cell Research*, **2006**, 312, 831-43	4.2	66
223	Combined genome-wide scan for prostate cancer susceptibility genes. *Journal of the National Cancer Institute*, **2004**, 96, 1240-7	9.7	65
222	Evaluation of serum and seminal plasma markers in the diagnosis of canine prostatic disorders. *Journal of Veterinary Internal Medicine*, **1995**, 9, 149-53	3.1	65
221	Polymorphic GGC repeats in the androgen receptor gene are associated with hereditary and sporadic prostate cancer risk. *Human Genetics*, **2002**, 110, 122-9	6.3	64
220	Frequent loss of chromosome arms 8p and 13q in collecting duct carcinoma (CDC) of the kidney. *Genes Chromosomes and Cancer*, **1995**, 12, 76-80	5	64
219	The effects of basic fibroblast growth factor and suramin on cell motility and growth of rat prostate cancer cells. *Journal of Urology*, **1991**, 145, 199-202	2.5	63
218	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. *Nature Genetics*, **2021**, 53, 65-75	36.3	62
217	GOLPH2 and MYO6: putative prostate cancer markers localized to the Golgi apparatus. *Prostate*, **2008**, 68, 1387-95	4.2	61
216	Genome-wide association study identifies a new locus JMJD1C at 10q21 that may influence serum androgen levels in men. *Human Molecular Genetics*, **2012**, 21, 5222-8	5.6	60

215	Systematic replication study of reported genetic associations in prostate cancer: Strong support for genetic variation in the androgen pathway. *Prostate*, **2006**, 66, 1729-43	4.2	60
214	Titin, a huge, elastic sarcomeric protein with a probable role in morphogenesis. *BioEssays*, **1991**, 13, 157-61	4.1	60
213	BIOLOGICAL AGGRESSIVENESS OF HEREDITARY PROSTATE CANCER: LONG-TERM EVALUATION FOLLOWING RADICAL PROSTATECTOMY. *Journal of Urology*, **1998**, 160, 660-663	2.5	59
212	Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality. *Cancer Epidemiology Biomarkers and Prevention*, **2011**, 20, 1928-36	4	58
211	Comprehensive assessment of DNA copy number alterations in human prostate cancers using Affymetrix 100K SNP mapping array. *Genes Chromosomes and Cancer*, **2006**, 45, 1018-32	5	58
210	Genomic organization of the human KAI1 metastasis-suppressor gene. *Genomics*, **1997**, 41, 25-32	4.3	57
209	Deletion of a small consensus region at 6q15, including the MAP3K7 gene, is significantly associated with high-grade prostate cancers. *Clinical Cancer Research*, **2007**, 13, 5028-33	12.9	57
208	Molecular advances in prostate cancer. *Current Opinion in Oncology*, **1997**, 9, 101-7	4.2	56
207	Identification of aryl hydrocarbon receptor as a putative Wnt/beta-catenin pathway target gene in prostate cancer cells. *Cancer Research*, **2004**, 64, 2523-33	10.1	56
206	Monocyte chemotactic protein-1 (MCP-1/CCL2) is associated with prostatic growth dysregulation and benign prostatic hyperplasia. *Prostate*, **2010**, 70, 473-81	4.2	55
205	Prostate cancer risk-associated variants reported from genome-wide association studies: meta-analysis and their contribution to genetic Variation. *Prostate*, **2010**, 70, 1729-38	4.2	55
204	Association of prostate cancer risk variants with clinicopathologic characteristics of the disease. *Clinical Cancer Research*, **2008**, 14, 5819-24	12.9	55
203	Stronger association between obesity and biochemical progression after radical prostatectomy among men treated in the last 10 years. *Clinical Cancer Research*, **2005**, 11, 2883-8	12.9	54
202	Prostate cancer risk associated loci in African Americans. *Cancer Epidemiology Biomarkers and Prevention*, **2009**, 18, 2145-9	4	53
201	Joint effect of HSD3B1 and HSD3B2 genes is associated with hereditary and sporadic prostate cancer susceptibility. *Cancer Research*, **2002**, 62, 1784-9	10.1	52
200	Generalizability of established prostate cancer risk variants in men of African ancestry. *International Journal of Cancer*, **2015**, 136, 1210-7	7.5	51
199	Sexually transmitted infections and prostatic inflammation/cell damage as measured by serum prostate specific antigen concentration. *Journal of Urology*, **2006**, 175, 1937-42	2.5	51
198	Identification of miR-30b-3p and miR-30d-5p as direct regulators of androgen receptor signaling in prostate cancer by complementary functional microRNA library screening. *Oncotarget*, **2016**, 7, 72593-72607	5.3	51

197	Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas. *Modern Pathology*, **2011**, 24, 1511-20	9.8	50
196	VITAMIN D RECEPTOR POLYMORPHISMS AND LETHAL PROSTATE CANCER. *Journal of Urology*, **1998**, 160, 1405-1409	2.5	49
195	Polymorphisms in the CYP1A1 gene are associated with prostate cancer risk. *International Journal of Cancer*, **2003**, 106, 375-8	7.5	49
194	LOSS OF HETEROZYGOSITY AT 12P12□13 IN PRIMARY AND METASTATIC PROSTATE ADENOCARCINOMA. *Journal of Urology*, **2000**, 164, 192-196	2.5	49
193	A novel prostate cancer susceptibility locus at 19q13. *Cancer Research*, **2009**, 69, 2720-3	10.1	48
192	Association of 17 prostate cancer susceptibility loci with prostate cancer risk in Chinese men. *Prostate*, **2010**, 70, 425-32	4.2	47
191	Genome-wide scan of 29,141 African Americans finds no evidence of directional selection since admixture. *American Journal of Human Genetics*, **2014**, 95, 437-44	11	46
190	Endoglin (CD105) as a urinary and serum marker of prostate cancer. *International Journal of Cancer*, **2009**, 124, 664-9	7.5	46
189	Evidence for a prostate cancer linkage to chromosome 20 in 159 hereditary prostate cancer families. *Human Genetics*, **2001**, 108, 430-5	6.3	46
188	Leveraging population admixture to characterize the heritability of complex traits. *Nature Genetics*, **2014**, 46, 1356-62	36.3	45
187	The G84E mutation of HOXB13 is associated with increased risk for prostate cancer: results from the REDUCE trial. *Carcinogenesis*, **2013**, 34, 1260-4	4.6	45
186	Cytokine profiling of prostatic fluid from cancerous prostate glands identifies cytokines associated with extent of tumor and inflammation. *Prostate*, **2008**, 68, 872-82	4.2	45
185	Interleukin-2 transfected prostate cancer cells generate a local antitumor effect in vivo. *Prostate*, **1994**, 24, 244-51	4.2	45
184	Evaluation of PPP2R2A as a prostate cancer susceptibility gene: a comprehensive germline and somatic study. *Cancer Genetics*, **2011**, 204, 375-81	2.3	44
183	Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations. *Prostate*, **2008**, 68, 1257-62	4.2	44
182	Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas. *Clinical Cancer Research*, **2015**, 21, 5619-29	12.9	43
181	Design, synthesis, and in vitro testing of alpha-methylacyl-CoA racemase inhibitors. *Journal of Medicinal Chemistry*, **2007**, 50, 2700-7	8.3	43
180	A comprehensive association study for genes in inflammation pathway provides support for their roles in prostate cancer risk in the CAPS study. *Prostate*, **2006**, 66, 1556-64	4.2	43

179	Genetic variability in inflammation pathways and prostate cancer risk. *Urologic Oncology: Seminars and Original Investigations*, **2007**, 25, 250-9	2.8	42
178	Genome-wide screen for prostate cancer susceptibility genes in men with clinically significant disease. *Prostate*, **2005**, 64, 356-61	4.2	42
177	Linkage and association of CYP17 gene in hereditary and sporadic prostate cancer. *International Journal of Cancer*, **2001**, 95, 354-9	7.5	42
176	No evidence for a role of BRCA1 or BRCA2 mutations in Ashkenazi Jewish families with hereditary prostate cancer. *Prostate*, **1999**, 39, 280-4	4.2	42
175	Identification of new differentially methylated genes that have potential functional consequences in prostate cancer. *PLoS ONE*, **2012**, 7, e48455	3.7	42
174	Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial. *Prostate*, **2016**, 76, 1120-9	4.2	42
173	The HOXB13 G84E Mutation Is Associated with an Increased Risk for Prostate Cancer and Other Malignancies. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 1366-72	4	41
172	Variation in IL10 and other genes involved in the immune response and in oxidation and prostate cancer recurrence. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 1774-82	4	40
171	Multiple genomic alterations on 21q22 predict various TMPRSS2/ERG fusion transcripts in human prostate cancers. *Genes Chromosomes and Cancer*, **2007**, 46, 972-80	5	40
170	Germ-line mutation of NKX3.1 cosegregates with hereditary prostate cancer and alters the homeodomain structure and function. *Cancer Research*, **2006**, 66, 69-77	10.1	40
169	Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of Missense Mutation in Prostate Cancer. *Clinical Cancer Research*, **2017**, 23, 4693-4703	12.9	39
168	Fine mapping of a region of chromosome 11q13 reveals multiple independent loci associated with risk of prostate cancer. *Human Molecular Genetics*, **2011**, 20, 2869-78	5.6	39
167	Association between sequence variants at 17q12 and 17q24.3 and prostate cancer risk in European and African Americans. *Prostate*, **2008**, 68, 691-7	4.2	39
166	Assignment of the human alpha-catenin gene (CTNNA1) to chromosome 5q21-q22. *Genomics*, **1994**, 19, 188-90	4.3	39
165	Infections and inflammation in prostate cancer. *American Journal of Clinical and Experimental Urology*, **2013**, 1, 3-11	1.6	39
164	Sequence variants of alpha-methylacyl-CoA racemase are associated with prostate cancer risk. *Cancer Research*, **2002**, 62, 6485-8	10.1	39
163	Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases. *British Journal of Cancer*, **2018**, 119, 347-356	8.7	38
162	A genome-wide assessment of variability in human serum metabolism. *Human Mutation*, **2013**, 34, 515-24	4.7	38

161	TMPRSS2-ERG gene fusion status in minute (minimal) prostatic adenocarcinoma. *Modern Pathology*, **2009**, 22, 1415-22	9.8	38
160	High-throughput screen identifies novel inhibitors of cancer biomarker α-methylacyl coenzyme A racemase (AMACR/P504S). *Molecular Cancer Therapeutics*, **2011**, 10, 825-38	6.1	38
159	Looking beyond morphology: cancer gene expression profiling using DNA microarrays. *Cancer Investigation*, **2003**, 21, 937-49	2.1	38
158	High mobility group protein I(Y): a candidate architectural protein for chromosomal rearrangements in prostate cancer cells. *Cancer Research*, **2002**, 62, 647-51	10.1	38
157	Large-scale association analysis in Asians identifies new susceptibility loci for prostate cancer. *Nature Communications*, **2015**, 6, 8469	17.4	37
156	Prostate cancer predisposition loci and risk of metastatic disease and prostate cancer recurrence. *Clinical Cancer Research*, **2011**, 17, 1075-81	12.9	37
155	Dynamic structure of the SPANX gene cluster mapped to the prostate cancer susceptibility locus HPCX at Xq27. *Genome Research*, **2005**, 15, 1477-86	9.7	37
154	Integration of multiethnic fine-mapping and genomic annotation to prioritize candidate functional SNPs at prostate cancer susceptibility regions. *Human Molecular Genetics*, **2015**, 24, 5603-18	5.6	35
153	Chromosome 8q24 risk variants in hereditary and non-hereditary prostate cancer patients. *Prostate*, **2008**, 68, 489-97	4.2	35
152	Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases. *Human Genetics*, **2015**, 134, 439-50	6.3	34
151	Inherited genetic markers discovered to date are able to identify a significant number of men at considerably elevated risk for prostate cancer. *Prostate*, **2011**, 71, 421-30	4.2	34
150	Deletion mapping at 12p12–13 in metastatic prostate cancer **1999**, 25, 270-276		34
149	A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer. *Prostate*, **2018**, 78, 607-615	4.2	33
148	Screening for familial and hereditary prostate cancer. *International Journal of Cancer*, **2016**, 138, 2579-91	7.5	33
147	Immunomodulatory IL-18 binding protein is produced by prostate cancer cells and its levels in urine and serum correlate with tumor status. *International Journal of Cancer*, **2011**, 129, 424-32	7.5	33
146	Genetic variants and family history predict prostate cancer similar to prostate-specific antigen. *Clinical Cancer Research*, **2009**, 15, 1105-11	12.9	33
145	Methylation and mutational analysis of p27(kip1) in prostate carcinoma. *Prostate*, **2001**, 48, 248-53	4.2	33
144	Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer. *Prostate*, **2009**, 69, 419-27	4.2	32

143	Meta-analysis of association of rare mutations and common sequence variants in the MSR1 gene and prostate cancer risk. *Prostate*, **2006**, 66, 728-37	4.2	32
142	Nucleotide resolution analysis of TMPRSS2 and ERG rearrangements in prostate cancer. *Journal of Pathology*, **2013**, 230, 174-83	9.4	31
141	Sequence variation within the 5R regulatory regions of the vitamin D binding protein and receptor genes and prostate cancer risk. *Prostate*, **2005**, 64, 272-82	4.2	31
140	An evaluation of PCR primer sets used for detection of Propionibacterium acnes in prostate tissue samples. *Prostate*, **2008**, 68, 1492-5	4.2	30
139	Integration of somatic deletion analysis of prostate cancers and germline linkage analysis of prostate cancer families reveals two small consensus regions for prostate cancer genes at 8p. *Cancer Research*, **2007**, 67, 4098-103	10.1	30
138	Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics. *Human Molecular Genetics*, **2007**, 16, 1271-8	5.6	30
137	Genome-wide copy-number variation analysis identifies common genetic variants at 20p13 associated with aggressiveness of prostate cancer. *Carcinogenesis*, **2011**, 32, 1057-62	4.6	29
136	Genetic and epigenetic inactivation of LPL gene in human prostate cancer. *International Journal of Cancer*, **2009**, 124, 734-8	7.5	28
135	Fine-mapping the putative chromosome 17q21-22 prostate cancer susceptibility gene to a 10 cM region based on linkage analysis. *Human Genetics*, **2007**, 121, 49-55	6.3	28
134	Inflammation, Microbiota, and Prostate Cancer. *European Urology Focus*, **2016**, 2, 374-382	5.1	28
133	Genome-wide association of familial prostate cancer cases identifies evidence for a rare segregating haplotype at 8q24.21. *Human Genetics*, **2016**, 135, 923-38	6.3	27
132	A genome-wide search for loci interacting with known prostate cancer risk-associated genetic variants. *Carcinogenesis*, **2012**, 33, 598-603	4.6	27
131	Comprehensive genetic evaluation of common E-cadherin sequence variants and prostate cancer risk: strong confirmation of functional promoter SNP. *Human Genetics*, **2005**, 118, 339-47	6.3	27
130	A major locus for hereditary prostate cancer in Finland: localization by linkage disequilibrium of a haplotype in the HPCX region. *Human Genetics*, **2005**, 117, 307-16	6.3	27
129	Molecular genetics and chromosomal alterations in prostate cancer. *Cancer*, **1995**, 75, 2004-2012	6.4	27
128	Evaluation of association of HNF1B variants with diverse cancers: collaborative analysis of data from 19 genome-wide association studies. *PLoS ONE*, **2010**, 5, e10858	3.7	24
127	HOXB13 interaction with MEIS1 modifies proliferation and gene expression in prostate cancer. *Prostate*, **2019**, 79, 414-424	4.2	24
126	Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease. *Human Genetics*, **2014**, 133, 347-56	6.3	23

125	The expression of AURKA is androgen regulated in castration-resistant prostate cancer. *Scientific Reports*, **2017**, 7, 17978	4.9	23
124	Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial. *Prostate*, **2015**, 75, 1403-18	4.2	23
123	Genetic and epigenetic inactivation of TNFRSF10C in human prostate cancer. *Prostate*, **2009**, 69, 327-35	4.2	23
122	Physical and transcript map of the hereditary prostate cancer region at xq27. *Genomics*, **2002**, 79, 41-50	4.3	23
121	Mannose Receptor-positive Macrophage Infiltration Correlates with Prostate Cancer Onset and Metastatic Castration-resistant Disease. *European Urology Oncology*, **2019**, 2, 429-436	6.7	23
120	Telomere length as a risk factor for hereditary prostate cancer. *Prostate*, **2014**, 74, 359-64	4.2	22
119	Functional annotation of risk loci identified through genome-wide association studies for prostate cancer. *Prostate*, **2011**, 71, 955-63	4.2	22
118	Large-scale fine mapping of the HNF1B locus and prostate cancer risk. *Human Molecular Genetics*, **2011**, 20, 3322-9	5.6	22
117	Genome-wide linkage analysis of 1,233 prostate cancer pedigrees from the International Consortium for Prostate Cancer Genetics using novel sumLINK and sumLOD analyses. *Prostate*, **2010**, 70, 735-44	4.2	22
116	Mutational analysis of PINX1 in hereditary prostate cancer. *Prostate*, **2004**, 60, 298-302	4.2	22
115	DNA methylation, molecular genetic, and linkage studies in prostate cancer. *Prostate*, **1996**, 29, 36-44	4.2	22
114	Refining the prostate cancer genetic association within the JAZF1 gene on chromosome 7p15.2. *Cancer Epidemiology Biomarkers and Prevention*, **2010**, 19, 1349-55	4	21
113	alpha-Catenin overrides Src-dependent activation of beta-catenin oncogenic signaling. *Molecular Cancer Therapeutics*, **2008**, 7, 1386-97	6.1	21
112	RNASEL Arg462Gln polymorphism and prostate cancer in PLCO. *Prostate*, **2007**, 67, 849-54	4.2	21
111	Improved biomarkers for prostate cancer: a definite need. *Journal of the National Cancer Institute*, **2004**, 96, 813-5	9.7	21
110	Familial aggregation of bothersome benign prostatic hyperplasia symptoms. *Urology*, **2003**, 61, 781-5	1.6	21
109	Effect of pentosan, a novel cancer chemotherapeutic agent, on prostate cancer cell growth and motility. *Prostate*, **1992**, 20, 233-41	4.2	21
108	Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data. *PLoS Genetics*, **2017**, 13, e1007001	6	20

107	Prevalence of the HOXB13 G84E prostate cancer risk allele in men treated with radical prostatectomy. *BJU International*, **2014**, 113, 830-5	5.6	20
106	Polymorphic variants in alpha-methylacyl-CoA racemase and prostate cancer. *Prostate*, **2007**, 67, 1487-97	4.2	20
105	Identification of a prostate cancer susceptibility locus on chromosome 7q11-21 in Jewish families. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 1939-44	11.5	20
104	Expression mapping at 12p12-13 in advanced prostate carcinoma. *International Journal of Cancer*, **2004**, 109, 668-72	7.5	20
103	A systematic comparison of exercise training protocols on animal models of cardiovascular capacity. *Life Sciences*, **2019**, 217, 128-140	6.8	20
102	Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer. *Clinical Cancer Research*, **2016**, 22, 448-58	12.9	19
101	Genome-wide association scan for variants associated with early-onset prostate cancer. *PLoS ONE*, **2014**, 9, e93436	3.7	19
100	Germline ATBF1 mutations and prostate cancer risk. *Prostate*, **2006**, 66, 1082-5	4.2	19
99	Germline sequence variants of the LZTS1 gene are associated with prostate cancer risk. *Cancer Genetics and Cytogenetics*, **2002**, 137, 1-7		19
98	Sequence variants in the human 25-hydroxyvitamin D3 1-alpha-hydroxylase (CYP27B1) gene are not associated with prostate cancer risk. *Prostate*, **2002**, 53, 175-8	4.2	19
97	Evaluation of SRD5A2 sequence variants in susceptibility to hereditary and sporadic prostate cancer. *Prostate*, **2003**, 56, 37-44	4.2	19
96	Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. *Oncogene*, **2020**, 39, 6935-6949	9.2	19
95	Validation of prostate cancer risk-related loci identified from genome-wide association studies using family-based association analysis: evidence from the International Consortium for Prostate Cancer Genetics (ICPCG). *Human Genetics*, **2012**, 131, 1095-103	6.3	18
94	Mutational analysis of SPANX genes in families with X-linked prostate cancer. *Prostate*, **2007**, 67, 820-8	4.2	18
93	Integrated clinical, whole-genome, and transcriptome analysis of multisampled lethal metastatic prostate cancer. *Journal of Physical Education and Sports Management*, **2016**, 2, a000752	2.8	18
92	Rare Germline Pathogenic Mutations of DNA Repair Genes Are Most Strongly Associated with Grade Group 5 Prostate Cancer. *European Urology Oncology*, **2020**, 3, 224-230	6.7	17
91	A peripheral circulating TH1 cytokine profile is inversely associated with prostate cancer risk in CLUE II. *Cancer Epidemiology Biomarkers and Prevention*, **2014**, 23, 2561-7	4	17
90	Molecular and cellular markers for metastatic prostate cancer. *Cancer and Metastasis Reviews*, **1993**, 12, 3-10	9.6	17

89	Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial. *Prostate*, **2017**, 77, 908-919	4.2	16
88	Mutational analysis of ETV6 in prostate carcinoma. *Prostate*, **2002**, 52, 305-10	4.2	16
87	Multiple antibodies to titin immunoreact with AHNAK and localize to the mitotic spindle machinery. *Cytoskeleton*, **2001**, 50, 101-13		16
86	A genetic variant near GATA3 implicated in inherited susceptibility and etiology of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). *Prostate*, **2017**, 77, 1213-1220	4.2	15
85	Genome-wide expression analysis of recently processed formalin-fixed paraffin embedded human prostate tissues. *Prostate*, **2009**, 69, 214-8	4.2	15
84	Association of CASP8 D302H polymorphism with reduced risk of aggressive prostate carcinoma. *Prostate*, **2010**, 70, 646-53	4.2	15
83	Identification and characterization of novel SNPs in CHEK2 in Ashkenazi Jewish men with prostate cancer. *Cancer Letters*, **2008**, 270, 173-80	9.9	15
82	Two-locus genome-wide linkage scan for prostate cancer susceptibility genes with an interaction effect. *Human Genetics*, **2006**, 118, 716-24	6.3	15
81	Differential effects of growth factor antagonists on neoplastic and normal prostatic cells. *Prostate*, **1990**, 17, 327-36	4.2	15
80	Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer. *Modern Pathology*, **2021**, 34, 1185-1193	9.8	15
79	Rare Variation in TET2 Is Associated with Clinically Relevant Prostate Carcinoma in African Americans. *Cancer Epidemiology Biomarkers and Prevention*, **2016**, 25, 1456-1463	4	14
78	Identification of a novel NBN truncating mutation in a family with hereditary prostate cancer. *Familial Cancer*, **2012**, 11, 595-600	3	14
77	Chromosomes 4 and 8 implicated in a genome wide SNP linkage scan of 762 prostate cancer families collected by the ICPCG. *Prostate*, **2012**, 72, 410-26	4.2	14
76	Comprehensive mutational analysis and mRNA isoform quantification of TP63 in normal and neoplastic human prostate cells. *Prostate*, **2009**, 69, 559-69	4.2	14
75	Interaction effect of PTEN and CDKN1B chromosomal regions on prostate cancer linkage. *Human Genetics*, **2004**, 115, 255-62	6.3	14
74	A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry. *European Urology*, **2020**, 78, 316-320	10.2	13
73	Identification of a novel germline SPOP mutation in a family with hereditary prostate cancer. *Prostate*, **2014**, 74, 983-90	4.2	13
72	Association of prostate cancer risk with SNPs in regions containing androgen receptor binding sites captured by ChIP-On-chip analyses. *Prostate*, **2012**, 72, 376-85	4.2	13

71	Comparison of two methods for estimating absolute risk of prostate cancer based on single nucleotide polymorphisms and family history. *Cancer Epidemiology Biomarkers and Prevention*, **2010**, 19, 1083-8	4	13
70	A nonclassic CCAAT enhancer element binding protein binding site contributes to alpha-methylacyl-CoA racemase expression in prostate cancer. *Molecular Cancer Research*, **2005**, 3, 110-8	6.6	13
69	G(1)/S cell cycle proteins as markers of aggressive prostate carcinoma. *Urology*, **2000**, 55, 316-22	1.6	13
68	Germline mutations in DNA repair genes are associated with bladder cancer risk and unfavourable prognosis. *BJU International*, **2018**, 122, 808-813	5.6	12
67	Genome-wide two-locus epistasis scans in prostate cancer using two European populations. *Human Genetics*, **2012**, 131, 1225-34	6.3	12
66	Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study. *European Urology Oncology*, **2021**, 4, 570-579	6.7	12
65	Xq27-28 deletions in prostate carcinoma. *Genes Chromosomes and Cancer*, **2003**, 37, 381-8	5	11
64	Genome-wide association study identifies loci at ATF7IP and KLK2 associated with percentage of circulating free PSA. *Neoplasia*, **2013**, 15, 95-101	6.4	10
63	Sequence variants in the 3R->5Rdeoxyribonuclease TREX2: identification in a genetic screen and effects on catalysis by the recombinant proteins. *Advances in Enzyme Regulation*, **2004**, 44, 37-49		10
62	AR splice variant 7 (AR-V7) and response to taxanes in men with metastatic castration-resistant prostate cancer (mCRPC).. *Journal of Clinical Oncology*, **2015**, 33, 138-138	2.2	10
61	Single-Nucleotide Polymorphism-Based Genetic Risk Score and Patient Age at Prostate Cancer Diagnosis. *JAMA Network Open*, **2019**, 2, e1918145	10.4	10
60	Do environmental factors modify the genetic risk of prostate cancer?. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 213-20	4	9
59	Germ-line sequence variants of PTEN do not have an important role in hereditary and non-hereditary prostate cancer susceptibility. *Journal of Human Genetics*, **2011**, 56, 496-502	4.3	9
58	Truncating variants in p53AIP1 disrupting DNA damage-induced apoptosis are associated with prostate cancer risk. *Cancer Research*, **2006**, 66, 10302-7	10.1	9
57	Genetic variants in cell cycle control pathway confer susceptibility to aggressive prostate carcinoma. *Prostate*, **2016**, 76, 479-90	4.2	9
56	Infectious mononucleosis, other infections and prostate-specific antigen concentration as a marker of prostate involvement during infection. *International Journal of Cancer*, **2016**, 138, 2221-30	7.5	9
55	Two-stage Study of Familial Prostate Cancer by Whole-exome Sequencing and Custom Capture Identifies 10 Novel Genes Associated with the Risk of Prostate Cancer. *European Urology*, **2021**, 79, 353-361	10.2	9
54	Genetic factors influencing prostate cancer risk in Norwegian men. *Prostate*, **2018**, 78, 186-192	4.2	9

53	Trichomonas vaginalis infection and prostate-specific antigen concentration: Insights into prostate involvement and prostate disease risk. *Prostate*, **2019**, 79, 1622-1628	4.2	8
52	Insight into infection-mediated prostate damage: Contrasting patterns of C-reactive protein and prostate-specific antigen levels during infection. *Prostate*, **2017**, 77, 1325-1334	4.2	8
51	A genome-wide survey over the ChIP-on-chip identified androgen receptor-binding genomic regions identifies a novel prostate cancer susceptibility locus at 12q13.13. *Cancer Epidemiology Biomarkers and Prevention*, **2011**, 20, 2396-403	4	8
50	Transmission/disequilibrium tests of androgen receptor and glutathione S-transferase pi variants in prostate cancer families. *International Journal of Cancer*, **2002**, 98, 938-42	7.5	8
49	Androgen receptor splice variant, AR-V7, and resistance to enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC).. *Journal of Clinical Oncology*, **2014**, 32, 5001-5001	2.2	8
48	Somatic molecular subtyping of prostate tumors from HOXB13 G84E carriers. *Oncotarget*, **2017**, 8, 22772-22788	5.3	8
47	Germline BLM mutations and metastatic prostate cancer. *Prostate*, **2020**, 80, 235-237	4.2	8
46	Germline HOXB13 G84E mutation carriers and risk to twenty common types of cancer: results from the UK Biobank. *British Journal of Cancer*, **2020**, 123, 1356-1359	8.7	8
45	Performance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality: A Population-based Prospective Analysis. *European Urology*, **2021**, 79, 419-426	10.2	8
44	Concept and benchmarks for assessing narrow-sense validity of genetic risk score values. *Prostate*, **2019**, 79, 1099-1105	4.2	7
43	DNA-Repair Gene Mutations in Metastatic Prostate Cancer. *New England Journal of Medicine*, **2016**, 375, 1802-1803	59.2	7
42	Current progress and questions in germline genetics of prostate cancer. *Asian Journal of Urology*, **2019**, 6, 3-9	2.7	7
41	Molecular Characterization and Clinical Outcomes of Primary Gleason Pattern 5 Prostate Cancer After Radical Prostatectomy. *JCO Precision Oncology*, **2019**, 3,	3.6	7
40	A multigenic approach to evaluating prostate cancer risk in a systematic replication study. *Cancer Genetics and Cytogenetics*, **2008**, 183, 94-8		6
39	Inherited susceptibility for aggressive prostate cancer. *Asian Journal of Andrology*, **2012**, 14, 415-8	2.8	6
38	Genomic and Clinicopathologic Characterization of -deficient Prostate Cancer. *Clinical Cancer Research*, **2020**, 26, 4869-4881	12.9	6
37	Validation of a prostate cancer polygenic risk score. *Prostate*, **2020**, 80, 1314-1321	4.2	6
36	Peripheral Zone Inflammation Is Not Strongly Associated With Lower Urinary Tract Symptom Incidence and Progression in the Placebo Arm of the Prostate Cancer Prevention Trial . *Prostate*, **2016**, 76, 1399-408	4.2	6

35	Prostate Cancer Predisposition. *Urologic Clinics of North America*, **2021**, 48, 283-296	2.9	6
34	gsSKAT: Rapid gene set analysis and multiple testing correction for rare-variant association studies using weighted linear kernels. *Genetic Epidemiology*, **2017**, 41, 297-308	2.6	5
33	Germline mutations in PPFIBP2 are associated with lethal prostate cancer. *Prostate*, **2018**, 78, 1222-1228	4.2	5
32	Genome-wide association study identifies genetic determinants of urine PCA3 levels in men. *Neoplasia*, **2013**, 15, 448-53	6.4	5
31	Does diabetes mellitus modify the association between 17q12 risk variant and prostate cancer aggressiveness?. *BJU International*, **2009**, 104, 1200-3	5.6	5
30	E1A transformed normal human prostate epithelial cells contain a 16q deletion. *Cancer Genetics and Cytogenetics*, **1998**, 103, 155-63		5
29	Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer. *JCI Insight*, **2021**, 6,	9.9	5
28	Key genes involved in the immune response are generally not associated with intraprostatic inflammation in men without a prostate cancer diagnosis: Results from the prostate cancer prevention trial. *Prostate*, **2016**, 76, 565-74	4.2	5
27	Inherited risk assessment of prostate cancer: it takes three to do it right. *Prostate Cancer and Prostatic Diseases*, **2020**, 23, 59-61	6.2	5
26	Lactoferrin CpG Island Hypermethylation and Decoupling of mRNA and Protein Expression in the Early Stages of Prostate Carcinogenesis. *American Journal of Pathology*, **2019**, 189, 2311-2322	5.8	4
25	Updated insights into genetic contribution to prostate cancer predisposition: focus on HOXB13. *Canadian Journal of Urology*, **2019**, 26, 12-13	0.8	4
24	Sustained influence of infections on prostate-specific antigen concentration: An analysis of changes over 10 years of follow-up. *Prostate*, **2018**, 78, 1024-1034	4.2	3
23	Polymorphisms influencing prostate-specific antigen concentration may bias genome-wide association studies on prostate cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 88-93	4	3
22	Distinct Genomic Alterations in Prostate Tumors Derived from African American Men. *Molecular Cancer Research*, **2020**, 18, 1815-1824	6.6	3
21	Post hoc Analysis for Detecting Individual Rare Variant Risk Associations Using Probit Regression Bayesian Variable Selection Methods in Case-Control Sequencing Studies. *Genetic Epidemiology*, **2016**, 40, 461-9	2.6	3
20	Germline copy number polymorphisms involving larger than 100 kb are uncommon in normal subjects. *Prostate*, **2007**, 67, 227-33	4.2	2
19	ATM loss in primary prostate cancer: Analysis of >1000 cases using a validated clinical-grade immunohistochemistry (IHC) assay.. *Journal of Clinical Oncology*, **2019**, 37, 5069-5069	2.2	2
18	Association of germline rare pathogenic mutations in guideline-recommended genes with prostate cancer progression: A meta-analysis. *Prostate*, **2022**, 82, 107-119	4.2	2

17	Association of prostate cancer polygenic risk score with number and laterality of tumor cores in active surveillance patients. *Prostate*, **2021**, 81, 703-709	4.2	2
16	Observed evidence for guideline-recommended genes in predicting prostate cancer risk from a large population-based cohort. *Prostate*, **2021**, 81, 1002-1008	4.2	2
15	Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine. *European Urology Open Science*, **2021**, 30, 47-62	0.9	2
14	Differences in inherited risk among relatives of hereditary prostate cancer patients using genetic risk score. *Prostate*, **2018**, 78, 1063	4.2	1
13	Evidence for a general cancer susceptibility locus at 3p24 in families with hereditary prostate cancer. *Cancer Letters*, **2005**, 219, 177-82	9.9	1
12	Feasibility and performance of a novel probe panel to detect somatic DNA copy number alterations in clinical specimens for predicting prostate cancer progression. *Prostate*, **2020**, 80, 1253-1262	4.2	1
11	Specific Detection of Prostate Cancer Cells in Urine by RNA In Situ Hybridization. *Journal of Urology*, **2021**, 206, 37-43	2.5	1
10	A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities **2011**, 71, 1656		1
9	Use of Aspirin and Statins in Relation to Inflammation in Benign Prostate Tissue in the Placebo Arm of the Prostate Cancer Prevention Trial. *Cancer Prevention Research*, **2020**, 13, 853-862	3.2	0
8	The somatic mutation landscape of germline CHEK2-altered prostate cancer.. *Journal of Clinical Oncology*, **2021**, 39, 5084-5084	2.2	0
7	Genetic Susceptibility for Low Testosterone in Men and Its Implications in Biology and Screening: Data from the UK Biobank. *European Urology Open Science*, **2021**, 29, 36-46	0.9	0
6	Association between pathogenic germline mutations in BRCA2 and ATM and tumor-infiltrating lymphocytes in primary prostate cancer. *Cancer Immunology, Immunotherapy*, **2021**, 1	7.4	0
5	GENETIC BASIS FOR PROSTATE CANCER **2011**, 39-52		
4	Effect of germline DNA repair gene mutations on outcomes in men with metastatic castration-resistant prostate cancer receiving first-line abiraterone and enzalutamide.. *Journal of Clinical Oncology*, **2018**, 36, 221-221	2.2	
3	Association of the HOXB13 G84E mutation with increased risk for prostate cancer and other malignancies.. *Journal of Clinical Oncology*, **2014**, 32, 1558-1558	2.2	
2	A novel method for detection of exfoliated prostate cancer cells in urine by RNA in situ hybridization. *Prostate Cancer and Prostatic Diseases*, **2021**, 24, 220-232	6.2	
1	Germline BRCA2, ATM and CHEK2 alterations shape somatic mutation landscapes in prostate cancer.. *Journal of Clinical Oncology*, **2022**, 40, 148-148	2.2	